Portal de investigação
Comparação de escala de qualidade de vida na insuficiência cardíaca com fração de ejeção reduzida quando realizada no domicílio ou na consulta hospitalar.
Dados básicos
Objectivos do projeto
Tipo de Estudo: Estudo Observacional – Iniciativa do Investigador; Subtipo: Outro; Fase: Cross-sectional; Natureza do Promotor: Academia – Tipo não comercial; Tipo de Centro: Unicêntrico - Cuidados Secundários - Centro de Ensaio: CHUSJ - Doença investigada: Insuficiência Cardíaca – Participantes recrutados: 30
Documentos
- Não há documentos
Participantes
Unidades de investigação
Stakeholders - Promotores
Outputs do ensaio clínico
Acute and chronic effects of levosimendan in the ZSF1 obese rat model of heart failure with preserved ejection fraction.
Moreira-Costa, L; (...); Lourenço, AP
Article. 10.1016/j.ejphar.2024.176336. 2024
Albiglutide in patients with type 2 diabetes and heart failure: a post-hoc analysis from Harmony Outcomes.
Ferreira, JP; (...); Neves, JS
Article. 10.1002/ejhf.2660. 2022
Assessing the influence of perfusion on cardiac microtissue maturation: A heart-on-chip platform embedding peristaltic pump capabilities
Cruz Moreira, D; (...); Rasponi, M
Article. 10.1002/bit.27836. 2021
Authors reply in response to a letter on "Standardized approach for extubation during extracorporeal membrane oxygenation in severe acute respiratory distress syndrome: a prospective observational study"
Roncon Albuquerque, R.; (...); Paiva, JA
Letter. 10.1186/s13613-023-01215-9. 2023
Changes in health-related quality of life and treatment effects in chronic heart failure: a meta-analysis.
Angelico Goncalves, A; (...); Ferreira, JP
Article. 10.1016/j.ijcard.2023.05.032. 2023
Effect of glucagon-like peptide-1 receptor agonists on cardiovascular events in overweight or obese adults without diabetes: A meta-analysis of placebo-controlled randomized trials.
Leite, AR; (...); Ferreira, JP
Article. 10.1111/dom.14707. 2022
Empagliflozin and risk of lower respiratory tract infection in heart failure with mildly reduced and preserved ejection fraction: An EMPEROR-Preserved analysis
Ferreira, JP; (...); Anker, S
Article. 10.1002/ejhf.3180. 2024
Enhancing Urological Cancer Treatment: Leveraging Vasodilator Synergistic Potential with 5-FU for Improved Therapeutic Outcomes.
Ribeiro, E; (...); Vale, N
Article. 10.3390/jcm13144113. 2024
FLEXIBLE PIEZOELECTRIC PATCHES FOR IMPROVEMENT OF HEART TISSUE ACTIVITY
Monteiro, LM; (...); Nascimento, DS
Meeting Abstract. 2022
GLP-1 Receptor Agonist Therapy With and Without SGLT2 Inhibitors in Patients With Type 2 Diabetes.
Neves, JS; (...); Md, JPF
Article. 10.1016/j.jacc.2023.05.048. 2023
Glucagon-like peptide 1 receptor agonists in patients with type 2 diabetes with and without chronic heart failure: A meta-analysis of randomized placebo-controlled outcome trials.
Ferreira, JP; (...); Neves, JS
Article. 10.1111/dom.14997. 2023
Glucagon-Like Peptide-1 Receptor Agonists Across the Spectrum of Heart Failure
Ferreira, J.; (...); Neves, J.
Review. 10.1210/clinem/dgad398. 2023
Impact of prediabetes in heart failure with preserved ejection fraction: the NetDiamond cohort
Borges-Canha, M; (...); Leite-Moreira, A
Meeting Abstract. 2021
In Vitro Drug Repurposing: Focus on Vasodilators.
Ribeiro, E; (...); Vale, N
Review. 10.3390/cells12040671. 2023
Inhibition of circulating dipeptidyl-peptidase 3 by procizumab in experimental septic shock reduces catecholamine exposure and myocardial injury
Garcia, Bruno; (...); Herpain, Antoine
Article. 10.1186/s40635-024-00638-3. 2024
Interleukin-6, infection and cardiovascular outcomes in acute heart failure: Findings from the EDIFICA registry
Vasques-Nóvoa, F; (...); Frioes, F
Article. 10.1016/j.cyto.2022.156053. 2022
Myocardial effects of angiotensin II compared to norepinephrine in an animal model of septic shock
Garcia, B; (...); Herpain, A
Article. 10.1186/s13054-022-04161-3. 2022
Myocardial oedema: pathophysiological basis and implications for the failing heart
Vasques?N?voa, F; (...); Roncon Albuquerque, R.
Review. 10.1002/ehf2.13775. 2022
Myocardial RNA Sequencing Reveals New Potential Therapeutic Targets in Heart Failure with Preserved Ejection Fraction
Inacio, JM; (...); Belo, JA
Article. 10.3390/biomedicines11082131. 2023
New Peptide Functionalized Nanostructured Lipid Carriers with CNS Drugs and Evaluation Anti-proliferative Activity.
Silva, S; (...); Vale, N
Article. 10.3390/ijms23137109. 2022
Pharmacological Targeting of Senescence with ABT-263 in Experimental Heart Failure with Preserved Ejection Fraction
Silva, E; (...); Nascimento, D.
Meeting Abstract. 10.1093/cvr/cvac066.107. 2022
Relaxin-2, pathophysiological insights and outcomes in heart failure with preserved ejection fraction: Findings from the NETDiamond cohort
Pintalhao, M; (...); Leite Moreira, A.
Article. 10.1016/j.ijcard.2022.07.037. 2022
Standardized approach for extubation during extracorporeal membrane oxygenation in severe acute respiratory distress syndrome: a prospective observational study
Roncon Albuquerque, R.; (...); Paiva, J.
Article. 10.1186/s13613-023-01185-y. 2023
TARGETING PREMATURE AGING TO IMPROVE HFPEF
Silva, E. D.; (...); Nascimento, D. S.
Meeting Abstract. 2023
The Effect of the Stress Induced by Hydrogen Peroxide and Corticosterone on Tryptophan Metabolism, Using Human Neuroblastoma Cell Line (SH-SY5Y).
Correia, AS; (...); Vale, N
Article. 10.3390/ijms24054389. 2023
The senolyitc drug ABT-263 reverses HFpEF-associated inflammation, endothelial inflammation and fibrosis
Silva, EDS; (...); Nascimento, DSN
Meeting Abstract. 2021
